Development of omics-based clinical tests for prognosis and therapy selection: The challenge of achieving statistical robustness and clinical utility

摘要

BackgroundMany papers have been published in biomedical journals reporting on the development of prognostic and therapy-guiding biomarkers or predictors developed from high-dimensional data generated by omics technologies. Few of these tests have advanced to routine clinical use.